SpinalCyte filed an Investigational New Drug Application with the FDA to expand its study of CybroCell Human Dermal Fibroblasts for the treatment of degenerative disc disease.
Biologics
The orthopedic biomaterials market is growing as the U.S. population ages, according to a Transparency Market Research report.
The American Academy of Orthopaedic Surgeons collaborated with the National Institutes of Arthritis, Musculoskeletal, and Skin Diseases to hold a symposium Feb. 15 through Feb. 17 at Stanford (Calif.) University on optimizing the use of biologics in orthopedic surgery.
The global spinal biologics market is expected to reach $2.4 billion by 2020, according to a MarketsandMarkets report. Here are eight companies leading the spinal biologics field.
Adam W. Anz, MD, is an orthopedic surgeon and sports medicine specialist at Gulf Breeze, Fla.-based Andrews Institute for Orthopaedics & Sports Medicine. He is the director of the Andrews Institute Regenerative Medicine Center and oversees the ATC Fellowship Program…
Advertisement
RTI Surgical accomplished a major milestone in April.
Here are 14 developments in spinal biologics in 2018 so far.
Patients who received intradiscal injections of SpinalCyte's new cell-based therapy CybroCell showed significantly improved disc height after six months.
Regenerative medicine company Mesoblast completed enrollment for its Phase 3 mesenchymal cell therapy trial to treat chronic low back pain due to degenerative disc disease.
The global orthobiologics market is predicted to exceed $5.52 billion in 2019, according to Transparency Market Research.